Biosergen completes the first Multiple Ascending Dose (MAD) cohort of BSG005 phase I trial
January 16, 2023: Biosegen AB (“Biosergen” or the “Company”) today announced that the Safety Review Committee has approved escalation to the next 6-volunteer cohort in the Multiple Ascending Dose (MAD) part of BSG005’s phase I trial.BSG005 is Biosergen’s lead development compound. It is a novel anti-fungal molecule from the group of polyene macrolides known for their broad anti-fungal and fungicidal effect, including on resistant and difficult-to-treat fungal strains, which make them unique within all antifungal drug classes. The successful completion of the phase I trial will demonstrate,